Yagi & Co., Ltd.: Exhibiting for the first time at ISPO Munich 2025, the world's largest trade fair for sports goods, based in Germany

20.11.2025 09:00:00 CET | Business Wire | Press Release

Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will be exhibiting for the first time at ISPO Munich, held in Munich, Germany, over three days from Sunday 30th November to Tuesday 2nd December this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119473772/en/

Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new products that address a wide range of health issues in areas such as sleep, beauty and sports through their blood circulation-promoting effects.

About ISPO

Based in Germany, it is one of the world's largest trade fairs specialising in sporting goods. Held since 1970, it brings together new products and brands across a wide range of sectors including outdoor, sports fashion, health & fitness, and sporting goods. Held not only in Germany (Munich) but also in China (Shanghai, Beijing), it attracts brands, buyers, and journalists from around the world. Wide range of genres: Outdoor, Action, Sports Fashion, Performance Sports, Textile Materials, Health & Fitness. Sustainability, including environmental protection and climate change measures, is a key theme, showcasing eco-conscious materials and technologies. New Product Launches: As a hub for the latest sports equipment, technologies, and trends, numerous new products and designs are unveiled. Awards are also held, incorporating feedback not only from exhibiting companies but also from general consumers.

Our Exhibition Content

Leveraging original materials developed by our Materials Division to address societal challenges—environmental sustainability, health, and heat countermeasures—our Apparel Division will propose textiles and products that blend its expertise in workwear with a sports aesthetic. These will be presented broadly, with a focus on the sports and outdoor sectors.

LAVATECH

Plant-derived Next-Generation Synthetic Fibre [PlaX™]

Through collaboration with the ‘PlaX™’ business—a new material combining polylactic acid with a plant-derived additive developed exclusively by Bioworks—we contribute to future environmental challenges as part of our eco-conscious initiatives. We strive to create new value through innovation and realise a sustainable society.
PlaX™ https://bioworks.co.jp/en/

COLDVEIL

COLDVEIL is a nylon material featuring three functions: heat shielding, quick-drying, and cooling sensation. Through the incorporation of titanium dioxide, it possesses a cooling sensation generated by absorbing heat and heat shielding properties. Making it an effective material for various applications in hot environments.

About YAGI

Founded in 1893, Yagi & Co., Ltd. is a leading company in textiles, apparel, lifestyle goods, and international brands, both in Japan and around the world. With approximately 83.3 billion yen in global revenue, the company is listed on the Tokyo Stock Exchange. Yagi is committed to its social and environmental responsibilities, guided by its philosophy of "Consistent Sincerity". For more information about Yagi, please visit https://www.yaginet.co.jp/en/index.html

ISPO Munich 2025 Overview

Dates: Sunday 30 November to Tuesday 2 December 2025
Venue: Messe München
Address: Messegelände, 81823 München
Official Website: https://www.ispo.com/en/munich

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119473772/en/

Contacts

Contact for inquiries regarding exhibition details
Contact: Katsuhiro Fukutani
Section 452, Fourth Business Division Apparel Part1 Headquarters
Email: fukutanik@yaginet.jp

For inquiries regarding this release:
Corporate Management/IR Group, Corporate Planning Department Yagi & Co., Ltd.
Public Relations: Motoki Kinebuchi Email: kinebuchim@yaginet.jp

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom